Trials / Completed
CompletedNCT05305547
A Study to Compare S-217622 With Placebo in Non-Hospitalized Participants With COVID-19
A Phase 3, Multicenter, Randomized, Double-Blind, 24-Week Study of the Clinical and Antiviral Effect of S-217622 Compared With Placebo in Non-Hospitalized Participants With COVID-19
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 2,093 (actual)
- Sponsor
- Shionogi · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main aim of this study is to evaluate the efficacy of S-217622 versus placebo among outpatient adults with mild and moderate COVID-19 starting intervention within 3 days of symptom onset.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | S-217622 | Administered as a round tablet. |
| DRUG | Placebo | Administered as a round tablet. |
Timeline
- Start date
- 2022-08-03
- Primary completion
- 2024-01-07
- Completion
- 2024-05-24
- First posted
- 2022-03-31
- Last updated
- 2025-09-16
Locations
196 sites across 17 countries: United States, Argentina, Brazil, Colombia, Ghana, India, Japan, Kenya, Malawi, Mexico, Pakistan, Peru, Philippines, Poland, South Africa, Thailand, Uganda
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05305547. Inclusion in this directory is not an endorsement.